Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LEGNNASDAQ:SRPTNASDAQ:TGTXNASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEGNLegend Biotech$36.39+2.5%$32.44$27.34▼$60.87$6.69B0.131.37 million shs1.32 million shsSRPTSarepta Therapeutics$17.65+3.2%$38.71$16.91▼$162.95$1.73B0.612.16 million shs4.55 million shsTGTXTG Therapeutics$35.38-1.7%$37.03$16.65▼$46.48$5.62B1.942.91 million shs1.13 million shsTVTXTravere Therapeutics$14.73-0.5%$16.90$7.72▼$25.29$1.31B0.751.61 million shs1.09 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEGNLegend Biotech+2.48%+4.84%+23.44%+12.60%-19.87%SRPTSarepta Therapeutics-0.06%-9.38%-54.67%-72.38%-89.18%TGTXTG Therapeutics-1.99%-1.56%+1.90%-4.66%+102.30%TVTXTravere Therapeutics+0.20%+2.14%-1.20%-15.14%+80.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLEGNLegend Biotech2.4136 of 5 stars3.51.00.00.03.41.70.6SRPTSarepta Therapeutics4.701 of 5 stars4.22.00.04.22.31.71.9TGTXTG Therapeutics3.7388 of 5 stars2.41.00.03.52.22.51.9TVTXTravere Therapeutics3.0228 of 5 stars4.43.00.00.01.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLEGNLegend Biotech 2.91Moderate Buy$76.20109.42% UpsideSRPTSarepta Therapeutics 2.44Hold$60.88245.00% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8015.32% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$32.14118.26% UpsideCurrent Analyst Ratings BreakdownLatest TVTX, LEGN, TGTX, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.006/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell6/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.006/17/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLEGNLegend Biotech$627.24M10.66N/AN/A$5.70 per share6.38SRPTSarepta Therapeutics$1.90B0.91$2.51 per share7.02$15.99 per share1.10TGTXTG Therapeutics$329M17.07$0.12 per share306.10$1.43 per share24.74TVTXTravere Therapeutics$233.18M5.61N/AN/A$0.76 per share19.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.61N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24147.6035.38N/A10.13%18.88%7.05%8/5/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)Latest TVTX, LEGN, TGTX, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLEGNLegend BiotechN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLEGNLegend Biotech0.305.205.07SRPTSarepta Therapeutics1.004.022.46TGTXTG Therapeutics1.034.023.04TVTXTravere Therapeutics9.462.052.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLEGNLegend Biotech70.89%SRPTSarepta Therapeutics86.68%TGTXTG Therapeutics58.58%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipLEGNLegend Biotech0.02%SRPTSarepta Therapeutics7.70%TGTXTG Therapeutics10.64%TVTXTravere Therapeutics4.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableTVTXTravere Therapeutics46088.81 million85.20 millionOptionableTVTX, LEGN, TGTX, and SRPT HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC WainwrightJuly 1 at 8:40 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - MorningstarJune 29 at 11:02 PM | morningstar.comMTravere Therapeutics Inc News (TVTX) - Investing.comJune 27, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 23, 2025 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 23, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by BrokeragesJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 16, 2025 | accessnewswire.comAEquities Analysts Set Expectations for TVTX FY2025 EarningsJune 16, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TVTX Q2 Earnings?June 16, 2025 | marketbeat.comTravere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdlesJune 15, 2025 | investing.comAssenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)June 15, 2025 | marketbeat.comHC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI BreakthroughsJune 14, 2025 | finance.yahoo.comHC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI BreakthroughsJune 13, 2025 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 13, 2025 | accessnewswire.comAQ4 EPS Estimate for Travere Therapeutics Lowered by AnalystJune 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 11, 2025 | accessnewswire.comACantor Fitzgerald Predicts TVTX FY2026 EarningsJune 11, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given "Buy" Rating at HC WainwrightJune 11, 2025 | marketbeat.comCitigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock PriceJune 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, LEGN, TGTX, and SRPT Company DescriptionsLegend Biotech NASDAQ:LEGN$36.39 +0.90 (+2.53%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Sarepta Therapeutics NASDAQ:SRPT$17.64 +0.55 (+3.19%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$35.38 -0.61 (-1.70%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Travere Therapeutics NASDAQ:TVTX$14.73 -0.07 (-0.49%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
